Veracyte Inc (NASDAQ: VCYT) has a higher price-to-earnings ratio of 105.58x compared to its average ratio. VCYT has 36-month beta value of 2.01. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 1 as “sell.”
The public float for VCYT is 76.84M, and currently, short sellers hold a 4.30% ratio of that float. The average trading volume of VCYT on March 26, 2025 was 897.72K shares.
VCYT) stock’s latest price update
Veracyte Inc (NASDAQ: VCYT) has experienced a decline in its stock price by -3.95 compared to its previous closing price of 33.69. However, the company has seen a gain of 1.83% in its stock price over the last five trading days. zacks.com reported 2025-03-26 that The mean of analysts’ price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
VCYT’s Market Performance
VCYT’s stock has risen by 1.83% in the past week, with a monthly drop of -3.29% and a quarterly drop of -20.86%. The volatility ratio for the week is 4.46% while the volatility levels for the last 30 days are 6.01% for Veracyte Inc The simple moving average for the past 20 days is 0.30% for VCYT’s stock, with a -4.09% simple moving average for the past 200 days.
Analysts’ Opinion of VCYT
Many brokerage firms have already submitted their reports for VCYT stocks, with Craig Hallum repeating the rating for VCYT by listing it as a “Buy.” The predicted price for VCYT in the upcoming period, according to Craig Hallum is $45 based on the research report published on March 20, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see VCYT reach a price target of $37, previously predicting the price at $38. The rating they have provided for VCYT stocks is “Neutral” according to the report published on December 05th, 2024.
Wolfe Research gave a rating of “Outperform” to VCYT, setting the target price at $50 in the report published on November 15th of the previous year.
VCYT Trading at -14.89% from the 50-Day Moving Average
After a stumble in the market that brought VCYT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.61% of loss for the given period.
Volatility was left at 6.01%, however, over the last 30 days, the volatility rate increased by 4.46%, as shares sank -7.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.54% lower at present.
During the last 5 trading sessions, VCYT rose by +2.93%, which changed the moving average for the period of 200-days by +52.78% in comparison to the 20-day moving average, which settled at $32.28. In addition, Veracyte Inc saw -18.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCYT starting from Leite John, who sale 7,411 shares at the price of $31.66 back on Mar 07 ’25. After this action, Leite John now owns 100,249 shares of Veracyte Inc, valued at $234,630 using the latest closing price.
JOHN LEITE, the Officer of Veracyte Inc, proposed sale 7,411 shares at $32.51 during a trade that took place back on Mar 07 ’25, which means that JOHN LEITE is holding shares at $240,932 based on the most recent closing price.
Stock Fundamentals for VCYT
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.66 for the gross margin
The net margin for Veracyte Inc stands at 0.05. The total capital return value is set at 0.01. Equity return is now at value 2.17, with 1.95 for asset returns.
Based on Veracyte Inc (VCYT), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 1.48. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 8335.5.
Currently, EBITDA for the company is 49.2 million with net debt to EBITDA at -3.99. When we switch over and look at the enterprise to sales, we see a ratio of 5.24. The receivables turnover for the company is 9.58for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.73.
Conclusion
To put it simply, Veracyte Inc (VCYT) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
